NLM 001
Alternative Names: NLM-001Latest Information Update: 23 Jan 2023
At a glance
- Originator Nelum
- Developer Agenus; Nelum
- Class Antineoplastics; Small molecules
- Mechanism of Action Hedgehog protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pancreatic cancer
- Discontinued Medulloblastoma
Most Recent Events
- 23 Jan 2023 Discontinued - Phase-I for Medulloblastoma in USA (unspecified route), before January 2023 (Agenus pipeline, January 2023)
- 01 Sep 2021 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in Spain (NCT04827953)
- 28 Jan 2021 Phase-I clinical trials in Medulloblastoma in USA (unspecified route) before January 2021 (Nelum's pipeline, January 2021)